Reactions 1704, p333 - 2 Jun 2018 Infusion reaction: case report In a retrospective data collection study, one patient [age and sex not stated] was described, who developed infusion reaction during treatment with rituximab for chronic immune thrombocytopenia (cITP). The patient was administered rituximab 375 mg/m weekly for 4 weeks. The patient developed grade 2 infusion reaction; however, the treatment was not discontinued [time to reaction onset and outcome not stated]. Author comment: "[One] patient had a Grade 2 infusion reaction according to NCI-CTC criteria but did not require discontinuation". Kundu S, et al. Single hospital retrospective review of the use of monoclonal antibody and its biosimilar truxima in chronic immune thrombocytopenia. British Journal of Haematology 181 (Suppl. 1): 163 abstr. BSH18-EP-010, Apr 2018. Available from: URL: http://doi.org/10.1111/bjh.15226 [abstract] - United Kingdom 803323279 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera